PTCDrug Approval•globenewswire•
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Sentiment:Positive (85)
Summary
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 18, 2025 by globenewswire